|
Hyperalgesia
|
0.310 |
Biomarker
|
phenotype |
BEFREE |
The aim of the present study was to identify whether ephrinB-EphB signaling could contribute to hyperalgesia through ERK5/CREB pathway.
|
28535565 |
2017 |
|
Hyperalgesia
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
In contrast, there was no change in ERK5 phosphorylation in the spinal dorsal horn.The i.t. administration of ERK5 antisense oligodeoxynucleotide reversed heat hyperalgesia, but not mechanical allodynia, produced by capsaicin injection.
|
17237256 |
2007 |
|
Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition.
|
29507229 |
2018 |
|
Allodynia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Intensity-dependent activation of extracellular signal-regulated protein kinase 5 in sensory neurons contributes to pain hypersensitivity.
|
17237256 |
2007 |
|
Hyperalgesia, Primary
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Intensity-dependent activation of extracellular signal-regulated protein kinase 5 in sensory neurons contributes to pain hypersensitivity.
|
17237256 |
2007 |
|
Hyperalgesia, Secondary
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Intensity-dependent activation of extracellular signal-regulated protein kinase 5 in sensory neurons contributes to pain hypersensitivity.
|
17237256 |
2007 |
|
Tactile Allodynia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Intensity-dependent activation of extracellular signal-regulated protein kinase 5 in sensory neurons contributes to pain hypersensitivity.
|
17237256 |
2007 |
|
Hyperalgesia, Thermal
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Intensity-dependent activation of extracellular signal-regulated protein kinase 5 in sensory neurons contributes to pain hypersensitivity.
|
17237256 |
2007 |
|
Mechanical Allodynia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
In contrast, there was no change in ERK5 phosphorylation in the spinal dorsal horn.The i.t. administration of ERK5 antisense oligodeoxynucleotide reversed heat hyperalgesia, but not mechanical allodynia, produced by capsaicin injection.
|
17237256 |
2007 |
|
Alzheimer's Disease
|
0.110 |
Biomarker
|
disease |
BEFREE |
The optimized TAT-NGF-RA-CURC-QU-CL/PA-lip efficaciously down-regulated the expressions of phosphorylated extracellular signal-regulated protein kinase 1/2 (p-ERK1/2), c-Jun N-terminal protein kinase, p38, tau at serine 202 and caspase-3, and up-regulated the expressions of p-ERK5 and p-cyclic adenosine monophosphate response element-binding protein in Alzheimer's disease Wistar rat model.
|
30716553 |
2019 |
|
Alzheimer's Disease
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide analysis of genetic predisposition to Alzheimer's disease and related sex disparities.
|
30636644 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MAPK7 expression was also upregulated in all the breast cancer cells and suppression of miR-155 resulted in its downregulation.
|
31424663 |
2020 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MAPK7 expression was also upregulated in all the breast cancer cells and suppression of miR-155 resulted in its downregulation.
|
31424663 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extracellular signal-regulated kinase 5 (ERK5) is now considered a key regulator of breast cancer cell proliferation, migration and invasion.
|
30952431 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The selective ERK5 inhibitor described herein provides a lead for further development into a tool compound for more extensive studies seeking to examine the role of ERK5 signalling in cancer and other diseases.
|
31212132 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on that, in this review, we pinpoint the hallmark-specific role of ERK5 in cancer in order to identify biological features that will potentially benefit from ERK5 targeting.
|
30901834 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, ERK5 knockdown strongly radiosensitized A549 and LLC tumor xenografts to inhibition, with a higher apoptotic response and reduced tumor neovascularization.
|
30804322 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In particular, it has been reported that ERK5 is a key signaling molecule involved in almost all the biological features of cancer cells so that its targeting is emerging as a promising strategy to suppress tumor growth and spreading.
|
30901834 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DUSP6/MKP3 is a dual-specific phosphatase that regulates extracellular regulated kinase ERK1/2 and ERK5 activity, with an increasingly recognized role as tumor suppressor.
|
31027181 |
2019 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, the decreased expression of BMK1 inhibits tumorigenesis, leading to the broad consensus that it functions as cell‑autonomous epithelial tumor promoter.
|
31322249 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extracellular signal-regulated kinase 5 (ERK5) is now considered a key regulator of breast cancer cell proliferation, migration and invasion.
|
30952431 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Extracellular signal-regulated kinase 5 (ERK5) is now considered a key regulator of breast cancer cell proliferation, migration and invasion.
|
30952431 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, overexpression of MAPK7 could reverse the inhibitory effects on cell proliferation, migration and invasion in U2OS cells induced by miR-143-3p mimics.
|
31126193 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on that, in this review, we pinpoint the hallmark-specific role of ERK5 in cancer in order to identify biological features that will potentially benefit from ERK5 targeting.
|
30901834 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The selective ERK5 inhibitor described herein provides a lead for further development into a tool compound for more extensive studies seeking to examine the role of ERK5 signalling in cancer and other diseases.
|
31212132 |
2019 |